EcoR1 Capital Takes 10.0% Stake in Allovir (ALVR)

TL;DR

**EcoR1 Capital just bought 10% of Allovir, signaling big institutional confidence!**

AI Summary

EcoR1 Capital, LLC, a Delaware-based investment firm, has reported a significant stake in Allovir, Inc. (ALVR), a biotechnology company. As of January 22, 2024, EcoR1 Capital beneficially owns 10,000,000 shares of Allovir's Common Stock, representing 10.0% of the company. This filing indicates a notable institutional investor believes in Allovir's future, which could signal confidence to current and potential shareholders.

Why It Matters

A major institutional investor like EcoR1 Capital taking a 10.0% stake suggests they see significant value or potential in Allovir, which can be a positive signal for other investors.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, which generally reduces perceived risk by showing external validation of the company's prospects.

Analyst Insight

A smart investor would research EcoR1 Capital's investment thesis and Allovir's recent developments to understand the potential reasons behind this significant institutional stake, potentially considering it a positive signal for Allovir's future prospects.

Key Numbers

• 10,000,000 — Shares Beneficially Owned (This is the total number of Allovir shares EcoR1 Capital, LLC now controls.)
• 10.0% — Ownership Percentage (This represents a significant stake, indicating EcoR1 Capital is a major shareholder in Allovir.)

Key Players & Entities

• EcoR1 Capital, LLC (company) — the reporting person acquiring shares
• Allovir, Inc. (company) — the subject company whose shares were acquired
• 10,000,000 (dollar_amount) — number of shares beneficially owned by EcoR1 Capital
• 10.0% (dollar_amount) — percentage of Allovir's class of securities owned by EcoR1 Capital
• January 22, 2024 (date) — date of the event requiring the filing
• Delaware (company) — state of incorporation for EcoR1 Capital, LLC

Forward-Looking Statements

• Other institutional investors may take a closer look at Allovir (ALVR) due to EcoR1 Capital's significant stake. (Allovir, Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• alvr13g.htm (SC 13G) — 45KB
• 0000935836-24-000088.txt ( ) — 47KB

Ownership

Item 4. Ownership. See Items 5-9 and 11 of the cover page for each Filer. The percentages reported in this Schedule 13G are based on 114,063,336 shares of Common Stock outstanding as of October 27, 2023, as reported on the Form 10-Q filed by the Issuer on November 2, 2023.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable.

Certification

Item 10. Certification. Certification of EcoR1 and Mr. Nodelman: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Certification of Qualified Fund: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 6 CUSIP No. 019818103 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated:February 1, 2024 EcoR1 CAPITAL, LLC By: /s/ Oleg Nodelman Oleg Nodelman, Manager /s/ Oleg Nodelman Oleg Nodelman EcoR1 CAPITAL FUND QUALIFIED, L.P. By:EcoR1 Capital, LLC, General Partner By: /s/ Oleg Nodelman Oleg Nodelman, Manager 7 CUSIP No. 019818103 EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by

View Full Filing

View this SC 13G filing on SEC EDGAR